Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:RCUS - US03969F1093 - Common Stock

25.56 USD
+1.28 (+5.27%)
Last: 11/26/2025, 8:04:00 PM
25.9886 USD
+0.43 (+1.68%)
After Hours: 11/26/2025, 8:04:00 PM
Fundamental Rating

2

Overall RCUS gets a fundamental rating of 2 out of 10. We evaluated RCUS against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of RCUS have multiple concerns. RCUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCUS had negative earnings in the past year.
RCUS had a negative operating cash flow in the past year.
In the past 5 years RCUS reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: RCUS reported negative operating cash flow in multiple years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

With a decent Return On Assets value of -35.01%, RCUS is doing good in the industry, outperforming 63.23% of the companies in the same industry.
RCUS has a Return On Equity (-78.21%) which is in line with its industry peers.
Industry RankSector Rank
ROA -35.01%
ROE -78.21%
ROIC N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCUS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RCUS has more shares outstanding
Compared to 1 year ago, RCUS has a worse debt to assets ratio.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.79, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
RCUS has a better Altman-Z score (0.79) than 63.60% of its industry peers.
A Debt/Equity ratio of 0.22 indicates that RCUS is not too dependend on debt financing.
The Debt to Equity ratio of RCUS (0.22) is worse than 66.60% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Altman-Z 0.79
ROIC/WACCN/A
WACC8.6%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 3.65 indicates that RCUS has no problem at all paying its short term obligations.
RCUS's Current ratio of 3.65 is in line compared to the rest of the industry. RCUS outperforms 45.03% of its industry peers.
A Quick Ratio of 3.65 indicates that RCUS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.65, RCUS is in line with its industry, outperforming 47.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.65
Quick Ratio 3.65
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for RCUS have decreased by -9.21% in the last year.
The Revenue has decreased by -8.75% in the past year.
Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 76.65% on average per year.
EPS 1Y (TTM)-9.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27%
Revenue 1Y (TTM)-8.75%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-45.83%

3.2 Future

Based on estimates for the next years, RCUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.29% on average per year.
The Revenue is expected to grow by 25.22% on average over the next years. This is a very strong growth
EPS Next Y-20.18%
EPS Next 2Y-17.19%
EPS Next 3Y-6.71%
EPS Next 5Y10.29%
Revenue Next Year-9.21%
Revenue Next 2Y-25.56%
Revenue Next 3Y-8.39%
Revenue Next 5Y25.22%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A cheap valuation may be justified as RCUS's earnings are expected to decrease with -6.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.19%
EPS Next 3Y-6.71%

More info and screens

0

5. Dividend

5.1 Amount

RCUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (11/26/2025, 8:04:00 PM)

After market: 25.9886 +0.43 (+1.68%)

25.56

+1.28 (+5.27%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28 2025-10-28/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners66.06%
Inst Owner Change-0.39%
Ins Owners5.33%
Ins Owner Change0.22%
Market Cap2.72B
Revenue(TTM)240.00M
Net Income(TTM)-341.00M
Analysts82.11
Price Target33.01 (29.15%)
Short Float %12.04%
Short Ratio6.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.48%
Min EPS beat(2)4.95%
Max EPS beat(2)100%
EPS beat(4)3
Avg EPS beat(4)28.92%
Min EPS beat(4)-8.41%
Max EPS beat(4)100%
EPS beat(8)6
Avg EPS beat(8)27.98%
EPS beat(12)10
Avg EPS beat(12)22.67%
EPS beat(16)13
Avg EPS beat(16)54.37%
Revenue beat(2)2
Avg Revenue beat(2)208.19%
Min Revenue beat(2)19.11%
Max Revenue beat(2)397.27%
Revenue beat(4)2
Avg Revenue beat(4)94.93%
Min Revenue beat(4)-24.87%
Max Revenue beat(4)397.27%
Revenue beat(8)6
Avg Revenue beat(8)97.65%
Revenue beat(12)8
Avg Revenue beat(12)69.17%
Revenue beat(16)11
Avg Revenue beat(16)103.35%
PT rev (1m)10.9%
PT rev (3m)10.9%
EPS NQ rev (1m)2.06%
EPS NQ rev (3m)-0.3%
EPS NY rev (1m)2.62%
EPS NY rev (3m)3.09%
Revenue NQ rev (1m)7.8%
Revenue NQ rev (3m)13.44%
Revenue NY rev (1m)2.06%
Revenue NY rev (3m)2.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.33
P/FCF N/A
P/OCF N/A
P/B 6.24
P/tB 6.24
EV/EBITDA N/A
EPS(TTM)-3.44
EYN/A
EPS(NY)-4.26
Fwd EYN/A
FCF(TTM)-4.36
FCFYN/A
OCF(TTM)-4.34
OCFYN/A
SpS2.26
BVpS4.1
TBVpS4.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -35.01%
ROE -78.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20%
Cap/Sales 0.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.65
Quick Ratio 3.65
Altman-Z 0.79
F-Score1
WACC8.6%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27%
EPS Next Y-20.18%
EPS Next 2Y-17.19%
EPS Next 3Y-6.71%
EPS Next 5Y10.29%
Revenue 1Y (TTM)-8.75%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-45.83%
Revenue Next Year-9.21%
Revenue Next 2Y-25.56%
Revenue Next 3Y-8.39%
Revenue Next 5Y25.22%
EBIT growth 1Y-25.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.25%
EBIT Next 3Y-2.73%
EBIT Next 5YN/A
FCF growth 1Y-51.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.58%
OCF growth 3YN/A
OCF growth 5YN/A

ARCUS BIOSCIENCES INC / RCUS FAQ

What is the ChartMill fundamental rating of ARCUS BIOSCIENCES INC (RCUS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCUS.


What is the valuation status of ARCUS BIOSCIENCES INC (RCUS) stock?

ChartMill assigns a valuation rating of 0 / 10 to ARCUS BIOSCIENCES INC (RCUS). This can be considered as Overvalued.


What is the profitability of RCUS stock?

ARCUS BIOSCIENCES INC (RCUS) has a profitability rating of 1 / 10.


What is the expected EPS growth for ARCUS BIOSCIENCES INC (RCUS) stock?

The Earnings per Share (EPS) of ARCUS BIOSCIENCES INC (RCUS) is expected to decline by -20.18% in the next year.